Pituitary Disorders: Prolactinoma, Acromegaly, and Panhypopituitarism

Pituitary disorders encompass a spectrum of conditions affecting the anterior and posterior pituitary gland, with prolactinoma, acromegaly, and panhypopituitarism representing three major clinical entities with distinct pathophysiological mechanisms.

[KEY_CONCEPT] The pituitary gland consists of the adenohypophysis (anterior pituitary) secreting ACTH, TSH, FSH, LH, GH, and prolactin, and the neurohypophysis (posterior pituitary) releasing ADH and oxytocin.

Prolactinoma

Prolactinomas are the most common functional pituitary adenomas, accounting for 40-50% of all pituitary tumors. They arise from lactotroph cells and are classified as:

• Microprolactinomas: <10 mm diameter
• Macroprolactinomas: ≥10 mm diameter

[HIGH_YIELD] Dopamine normally inhibits prolactin secretion through D2 receptors. Prolactinomas develop resistance to dopamine inhibition, leading to autonomous prolactin hypersecretion.

Acromegaly

Acromegaly results from excessive growth hormone (GH) secretion, typically from a somatotroph adenoma. Prevalence is 40-70 cases per million population with incidence of 3-4 cases per million annually.

[CLINICAL_PEARL] IGF-1 (insulin-like growth factor-1) mediates most of GH's growth-promoting effects and serves as the primary screening marker due to its longer half-life compared to GH's pulsatile secretion.

Panhypopituitarism

Panhypopituitarism involves deficiency of multiple anterior pituitary hormones. Etiology includes:

• Pituitary adenomas (most common)
• Craniopharyngioma
• Sheehan syndrome (postpartum pituitary necrosis)
• Lymphocytic hypophysitis
• Traumatic brain injury
• Radiation therapy

[HIGH_YIELD] Hormone deficiencies typically follow a predictable sequence: GH and gonadotropins are lost first, followed by TSH, then ACTH (most life-threatening).

Prolactinoma Clinical Features

Women (reproductive age):

• Galactorrhea (80-90% of cases)
• Oligomenorrhea or amenorrhea
• Infertility
• Decreased libido
• Osteoporosis (due to estrogen deficiency)

Men:

• Erectile dysfunction and decreased libido
• Infertility and gynecomastia
• Galactorrhea (rare, <25% of cases)
• Mass effect symptoms (more common due to delayed diagnosis)

[CLINICAL_PEARL] Men typically present later with macroprolactinomas because early symptoms are subtle, whereas women present earlier due to obvious menstrual irregularities.

Acromegaly Clinical Features

Somatic manifestations:

• Acral enlargement: hands, feet, facial features
• Prognathism (jaw protrusion) and macroglossia
• Coarse facial features and skin tags
• Carpal tunnel syndrome (50% of patients)
• Arthropathy and kyphoscoliosis

Metabolic complications:

• Diabetes mellitus (25-50% of patients)
• Hypertension (35% of patients)
• Sleep apnea (60-80% of patients)
• Cardiomyopathy and left ventricular hypertrophy

[HIGH_YIELD] Cardiovascular disease is the leading cause of death in acromegaly, with 2-3 fold increased mortality if untreated.

Panhypopituitarism Clinical Features

ACTH deficiency (most dangerous):

• Fatigue, weakness, weight loss
• Hypotension and hyponatremia
• Hypoglycemia and decreased stress response

TSH deficiency:

• Cold intolerance, fatigue, weight gain
• Bradycardia and constipation

Gonadotropin deficiency:

• Amenorrhea/oligomenorrhea in women
• Erectile dysfunction and decreased libido in men
• Infertility in both sexes

GH deficiency (adults):

• Decreased muscle mass and increased abdominal fat
• Decreased bone density
• Fatigue and decreased quality of life

[KEY_CONCEPT] Mass effect symptoms can occur with any large pituitary lesion: bitemporal hemianopia, headaches, and cranial nerve palsies.

Prolactinoma Diagnosis

Laboratory evaluation:

1. Serum prolactin level (fasting, morning sample)

   • Normal: <25 ng/mL (women), <20 ng/mL (men)
   • Microprolactinoma: 25-250 ng/mL
   • Macroprolactinoma: Usually >250 ng/mL

2. Rule out secondary causes:

   • Medications (antipsychotics, metoclopramide, SSRIs)
   • Hypothyroidism (TSH, free T4)
   • Chronic kidney disease
   • Pregnancy (β-hCG)

[HIGH_YIELD] Hook effect: Very large prolactinomas (>200 ng/mL) may show falsely normal prolactin due to antibody saturation. Request serial dilutions if suspected.

Imaging:

• MRI pituitary with gadolinium (gold standard)
• Visual field testing for macroadenomas

Acromegaly Diagnosis

Screening tests:

1. IGF-1 level (age and sex-adjusted)
   • Elevated IGF-1 suggests acromegaly
   • Normal IGF-1 makes acromegaly unlikely

Confirmatory testing: 2. Oral glucose tolerance test (OGTT)

• Normal response: GH suppresses to <1 ng/mL
• Acromegaly: GH fails to suppress or may paradoxically rise

[CLINICAL_PEARL] Random GH levels are unreliable due to pulsatile secretion, but GH >10 ng/mL is virtually diagnostic of acromegaly.

Additional testing:

• MRI pituitary to identify adenoma
• Visual field assessment
• Colonoscopy (increased colon cancer risk)
• Echocardiogram (cardiac assessment)
• Sleep study if sleep apnea suspected

Panhypopituitarism Diagnosis

Hormonal assessment algorithm:

Baseline Testing: ├── Morning cortisol (<3 μg/dL suggests ACTH deficiency) ├── Free T4 and TSH (low/low-normal suggests TSH deficiency) ├── IGF-1 (low suggests GH deficiency) ├── Testosterone (men) / Estradiol (women) ├── FSH/LH levels └── Prolactin level

Dynamic Testing (if baseline abnormal): ├── ACTH stimulation test │ ├── Standard dose (250 μg cosyntropin) │ └── Low dose (1 μg) if recent onset ├── Insulin tolerance test (gold standard for GH/ACTH) │ └── Contraindicated in: CAD, seizures, age >65 └── Alternative tests: ├── Glucagon stimulation test └── GHRH-arginine test

[HIGH_YIELD] Central vs. primary endocrine failure patterns:

Imaging:

• MRI pituitary with and without contrast
• Visual field testing
• Additional imaging based on suspected etiology

Prolactinoma Management

Medical therapy (first-line):

Dopamine Agonist Selection: ├── Cabergoline (preferred) │ ├── Starting dose: 0.25 mg twice weekly │ ├── Titrate every 4 weeks │ ├── Target: normalize prolactin, restore gonadal function │ └── Advantages: Better efficacy, tolerability │ └── Bromocriptine (alternative) ├── Starting dose: 1.25 mg daily with food ├── Titrate weekly to 2.5-15 mg daily └── Preferred in pregnancy

[CLINICAL_PEARL] Cabergoline achieves normalization of prolactin in 85-95% of patients and tumor shrinkage in 80-90% of cases.

Surgical indications:

• Dopamine agonist intolerance or resistance
• CSF leak from tumor
• Apoplexy with visual field defects
• Patient preference (young women desiring pregnancy)

Monitoring:

• Prolactin levels every 3 months initially, then every 6-12 months
• MRI at 1 year, then every 2-5 years
• Visual fields for macroadenomas
• Bone density in hypogonadal patients

Acromegaly Management

Treatment algorithm:

First-line Treatment: ├── Transsphenoidal Surgery │ ├── Macroadenomas: 60-70% cure rate │ ├── Microadenomas: 85-95% cure rate │ └── Goals: IGF-1 normalization, GH <2.5 ng/mL │ ├── If surgical cure not achieved: │ ├── Medical therapy │ │ ├── Somatostatin analogs (octreotide, lanreotide) │ │ ├── GH receptor antagonist (pegvisomant) │ │ └── Dopamine agonists (cabergoline) │ │ │ └── Radiation therapy │ ├── Conventional radiotherapy │ └── Stereotactic radiosurgery (Gamma Knife)

Medical therapy details:

Somatostatin analogs:

• Octreotide LAR: 10-30 mg IM monthly
• Lanreotide: 60-120 mg SC monthly
• Efficacy: IGF-1 normalization in 60-70%

[HIGH_YIELD] Pasireotide (newer somatostatin analog) is effective in octreotide-resistant patients but has higher diabetes risk.

Pegvisomant:

• GH receptor antagonist
• Daily SC injection: 10-30 mg
• Efficacy: IGF-1 normalization in >90%
• Monitor: Monthly liver function tests

Panhypopituitarism Management

Hormone replacement priorities:

1. ACUTE MANAGEMENT: └── Hydrocortisone (life-threatening if untreated) ├── Emergency: 100 mg IV q8h └── Maintenance: 15-25 mg daily (2/3 AM, 1/3 PM)

2. THYROID REPLACEMENT: └── Levothyroxine 1.6 μg/kg/day ├── Start AFTER cortisol replacement └── Monitor free T4 (not TSH)

3. SEX HORMONE REPLACEMENT: ├── Women: Estrogen/progesterone │ ├── Contraindications: breast cancer, VTE history │ └── Benefits: bone health, cardiovascular, QOL │ └── Men: Testosterone ├── Gel, injection, or patch └── Monitor: hematocrit, PSA

4. GROWTH HORMONE (adults): └── Consider if severe deficiency + symptoms ├── Starting dose: 0.2-0.3 mg daily └── Monitor: IGF-1 levels, side effects

[KEY_CONCEPT] Never start thyroid replacement before cortisol replacement in panhypopituitarism - can precipitate adrenal crisis.

Patient education:

• Sick day management: Double hydrocortisone dose
• Medical alert bracelet
• Injectable hydrocortisone for emergencies
• Regular monitoring and follow-up

Prolactinoma Complications

Untreated consequences:

• Osteoporosis and fracture risk (hypogonadism-induced)
• Cardiovascular disease (estrogen deficiency)
• Mass effect: Visual field defects, cranial nerve palsies
• Pituitary apoplexy (rare but life-threatening)

Treatment-related complications:

[CLINICAL_PEARL] Cardiac valvulopathy with dopamine agonists is dose-dependent and more common with pergolide (no longer recommended). Cabergoline at standard doses carries minimal risk.

Dopamine agonist side effects:

• Nausea, dizziness, fatigue (dose-dependent)
• Orthostatic hypotension
• Impulse control disorders (gambling, hypersexuality)
• Cardiac valve fibrosis (high cumulative doses)

Monitoring protocol:

• Echocardiogram: Baseline, then annually if cumulative cabergoline dose >2 mg
• Prolactin levels: Every 3-6 months
• Bone density: Every 2 years if hypogonadal

Acromegaly Complications

Cardiovascular (leading cause of death):

• Cardiomyopathy and heart failure
• Hypertension (35% prevalence)
• Arrhythmias and sudden cardiac death
• Accelerated atherosclerosis

Metabolic complications:

• Type 2 diabetes (25-50% prevalence)
• Insulin resistance and metabolic syndrome
• Dyslipidemia

Malignancy risk:

• Colorectal cancer (2-3 fold increased risk)
• Thyroid cancer
• Skin malignancies

[HIGH_YIELD] Mortality in acromegaly is 2-3 times higher than general population if untreated. Biochemical control (IGF-1 normalization) normalizes life expectancy.

Treatment complications:

Somatostatin analogs:

• Gallbladder disease (20-30% develop stones)
• Hyperglycemia (especially pasireotide)
• Injection site reactions
• GI symptoms (diarrhea, abdominal pain)

Surgical complications:

• CSF leak (5-10%)
• Pituitary hormone deficiency (5-15%)
• Diabetes insipidus (usually transient)

Panhypopituitarism Complications

Life-threatening complications:

• Adrenal crisis: Hypotension, shock, death
• Severe hypoglycemia
• Hyponatremia and electrolyte abnormalities

Long-term consequences:

• Osteoporosis (multiple hormone deficiencies)
• Cardiovascular disease (GH, thyroid, gonadal deficiencies)
• Cognitive impairment and depression
• Decreased muscle mass and increased mortality

[KEY_CONCEPT] Quality of life is significantly impaired in untreated panhypopituitarism. Comprehensive hormone replacement improves outcomes but requires lifelong therapy.

Replacement therapy monitoring:

Emergency management:

• Stress dose steroids: 100 mg hydrocortisone IV during illness/surgery
• Patient education: Medical alert identification
• Injectable hydrocortisone prescription for emergencies

Prolactinoma Prognosis

Treatment response rates:

• Cabergoline: 85-95% achieve prolactin normalization
• Tumor shrinkage: 80-90% show ≥50% volume reduction
• Visual field improvement: 90% if present initially
• Fertility restoration: 80-90% in women of reproductive age

Long-term outcomes:

• Microprolactinomas: Excellent prognosis, low risk of growth
• Macroprolactinomas: Good response to medical therapy, surgery rarely needed
• Pregnancy outcomes: Generally safe with close monitoring

[HIGH_YIELD] Dopamine agonist withdrawal: Possible in 10-20% of patients after 2-5 years of treatment, especially in microprolactinomas.

Recurrence rates:

• Medical therapy discontinuation: 80-90% recurrence
• Post-surgical: 10-50% depending on completeness of resection

Acromegaly Prognosis

Mortality outcomes:

• Untreated acromegaly: 2-3 fold increased mortality
• Biochemical control (IGF-1 <1.3× ULN): Normalized life expectancy
• Partial control: Intermediate mortality risk

Surgical cure rates:

• Microadenomas: 85-95% cure rate
• Macroadenomas: 60-70% cure rate
• Invasive tumors: <50% cure rate

[CLINICAL_PEARL] Biochemical remission criteria (Endocrine Society 2014):

• IGF-1 normal for age and sex
• Random GH <1 ng/mL or post-OGTT GH <0.4 ng/mL

Comorbidity improvement with treatment:

• Diabetes mellitus: Improves in 50-60% of patients
• Hypertension: Normalizes in 30-40%
• Sleep apnea: Improves in 60-80%
• Cardiomyopathy: Gradual improvement over years
• Arthropathy: Limited reversibility (structural changes)

Treatment durability:

• Medical therapy: Requires lifelong treatment
• Radiation therapy: 50-60% remission at 10 years
• Combination therapy: Often needed for optimal control

Panhypopituitarism Prognosis

Overall outcomes:

• With adequate replacement: Near-normal life expectancy
• Untreated: Significantly increased morbidity and mortality
• Partial replacement: Intermediate outcomes

Specific hormone outcomes:

ACTH deficiency:

• Excellent prognosis with hydrocortisone replacement
• Crisis prevention: Key to normal survival
• Stress management: Critical patient education component

Growth hormone deficiency:

• Adults: Improved quality of life, body composition, bone density
• Cardiovascular benefits: Reduced mortality in some studies
• Cost-effectiveness: Debated for adult GH replacement

Thyroid and gonadal replacement:

• High treatment satisfaction and symptom resolution
• Bone health: Significant improvement with combined replacement
• Fertility: Often restored with appropriate gonadotropin therapy

[KEY_CONCEPT] Recovery of pituitary function is possible in certain conditions:

• Inflammatory hypophysitis: 30-50% partial recovery
• Postoperative deficiency: Some recovery possible within 1 year
• Traumatic brain injury: Variable, may improve over 1-2 years

Quality of life factors:

• Comprehensive replacement: Better outcomes than partial
• Patient education: Critical for emergency management
• Regular monitoring: Prevents under- and over-replacement
• Multidisciplinary care: Endocrinology, ophthalmology, neurosurgery

Monitoring schedule for optimal outcomes:

• First year: Every 3 months
• Stable patients: Every 6-12 months
• Imaging: Every 1-5 years depending on underlying pathology
• Specialist referral: Maintain endocrinology follow-up indefinitely